AIDSMap reports.The U.S.-based phase IIa study used 250 volunteers to examine the level and persistence of islatravir in blood and tissue.
Volunteers aged 18 to 65 at a low risk of HIV infection were divided into three groups. One hundred volunteers received an monthly oral dosage of 60 milligrams for a period of six months, 100 received a 120mg oral dosage for six months, and the remaining 50 received a placebo over the same period.Drug levels were recorded immediately after dosing and each week during the first and sixth months of the study.
For the second through the fifth months, only the trough levels, or those measured immediately before the next dose, were recorded.The findings presented by Hillier were encouraging.